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DObjective: Prosthetic valve type selection combined with surgical ablation during left-sided heart valve
replacement in older individuals with atrial fibrillation remains controversial.
Methods: A total of 573 patients aged 60 years or older (median, 65; range, 60-84) who underwent left-sided
valve replacement surgery in the presence of atrial fibrillation from 1990 to 2010 were evaluated for all-cause
mortality during a median follow-up period of 58.0 months (interquartile range, 33.1-84.1).
Results: Mechanical and bioprosthetic valves were implanted in 356 (62.1%) and 217 (37.9%) patients,
respectively, and 203 patients (35.4%) underwent surgical ablation concomitantly. During the follow-up period,
166 patients died. The 5- and 10- year survival rate was 76.3%  2.1% and 58.4%  3.2%, respectively. On
Cox regression analysis, age (P<.001), diabetes (P ¼ .014), left ventricular ejection fraction (P ¼ .010), left
atrial size (P ¼ .038), the requirement for coronary bypass (P ¼ .015), and cardiopulmonary bypass time
(P< .001) emerged as significant and independent predictors of death. In addition, surgical ablation was
protective against all-cause mortality (hazard ratio, 0.63; P ¼ .033). The improved survival observed with
surgical ablation was verified by propensity score adjustment models (hazard ratio, 0.64; 95% confidence
interval, 0.30-0.99; P ¼ .046). The choice of prosthetic type, however, affected neither survival (P ¼ .79) nor
event-free survival (P ¼ .48).
Conclusions: Long-term survival after valve replacement in older individuals with atrial fibrillation was
affected by several preoperative characteristics and the performance of surgical ablation but not by the choice
of prosthesis. These findings suggest that surgical atrial fibrillation ablation should always be considered for
these patients, regardless of the prosthesis type used. (J Thorac Cardiovasc Surg 2014;147:1907-17)Valve replacement surgery remains a standard therapy for
symptomatic patients with severe heart valve disease,
whose dysfunctional valves are not amendable to repair.
When performing valve replacement surgery, the choice
of prosthetic valve type depends mostly on patient-related
factors, among which age has been regarded as the key
determining factor.1-3 Current guidelines suggest that
bioprosthetic implantation is a reasonable option for older
individuals because of the lower rates of anticoagulation-
related bleeding, despite comparable rates of valve
failure.2,3
However, this age-guided recommendation might
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The Journal of Thoracic and Carthromboembolism, such as those with atrial fibrillation
(AF). AF is the most common arrhythmia in patients
undergoing valve replacement surgery, and its prevalence
is reported to be as high as 30% to 50%.4 AF is regarded
as a marker of prolonged and advanced valve dysfunction
and has been reported to be associated with poor clinical
outcomes after heart valve surgery.5 Surgical ablation has
been recognized as an effective method of restoring
normal sinus rhythm fromAF and, consequently, has gained
popularity as a concomitant procedure during heart valve
surgery.5,6
Despite the progress in AF ablation surgery, the high rate
of AF recurrence in older individuals6,7 and concerns about
the increased surgical risks due to procedural complexity8
have hindered the routine combination of surgical ablation
in older individuals undergoing valve replacement surgery.
Furthermore, combining surgical ablation and valve
replacement surgery in patients with AF complicates the
choice of prosthetic valve type (mechanical vs bioprosthetic
valve) that will be implanted.
Thus, evaluation of the clinical outcomes in older
patients with AF undergoing valve replacement surgery
according to the choice of prosthetic valve type and the
performance of surgical ablation is important. In the reviewdiovascular Surgery c Volume 147, Number 6 1907
TABLE 1. Baseline characteristics stratified by surgical ablation
Characteristic
Ablation
group
Control
group
P
value
Patients (n) 203 370
Age (y) 66.3  4.8 66.6  5.4 .485
Male gender (%) 61 (30.0) 168 (45.4) <.001
NYHA functional class
I 40 (19.7) 46 (12.4)
II 79 (38.9) 134 (36.2)
III 77 (37.9) 156 (42.2)
IV 7 (3.4) 34 (9.2)
Diabetes mellitus 36 (17.7) 47 (12.7) .108
Hypertension 56 (27.6) 87 (23.5) .313
History of CVA/TIA 37 (18.2) 57 (15.4) .410
Previous cardiac surgery 10 (4.9) 37 (10.0) .038
Estimated GFR 70.5  18.2 67.3  21.7 .078
CHADS2 score
0 87 (42.9) 161 (43.5)
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass grafting
HR ¼ hazard ratio
INR ¼ international normalized ratio
LV ¼ left ventricular
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Dof previously published data, however, few studies were
found that had evaluated the clinical effect of these
procedural factors on the clinical outcomes in reasonably
sized cohorts. We, therefore, sought to evaluate the
long-term clinical outcomes of valve replacement surgery,
taking into account the type of prosthetic valve implanted
and the performance of concomitant surgical ablation, in
a reasonably sized cohort of older patients with AF.1 56 (27.6) 99 (26.8)
2 32 (15.8) 67 (18.1)
3 18 (8.9) 32 (8.6)
4 8 (3.9) 10 (2.7)
5 2 (1.0) 1 (0.3)
Echocardiographic data
LV ejection fraction (%) 53.9  8.9 53.5  11.2 .616
LV end-systolic dimension (mm) 35.9  8.1 38.0  9.4 .007
LV end-diastolic dimension (mm) 52.8  8.6 55.1  10.0 .003
Left atrial diameter (mm) 58.3  9.8 59.2  12.2 .364
RV-RA pressure gradient (mm Hg) 37.7  12.8 40.0  16.6 .074
Tricuspid regurgitation grade
0 11 (5.4) 39 (10.5)
1 46 (22.7) 114 (30.8)
2 48 (23.6) 79 (21.4)
3 54 (26.6) 61 (16.5)
4 44 (21.7) 77 (20.8)
Operation type
AV replacement 43 (21.2) 101 (27.3)
MV replacement 126 (62.1) 210 (56.8)
AV and MV replacement 34 (16.7) 59 (15.9)
Concomitant tricuspid repair 119 (58.6) 139 (37.6) <.001
Other concomitant surgery
CABG 22 (10.8) 43 (11.6) .777
Aorta replacement 3 (1.5) 11 (3.0) .268
Aortic crossclamp time (min) 109.9  36.3 84.7  42.6 <.001
Cardiopulmonary bypass time (min) 201.1  53.9 140.7  77.2 .035
Logistic EuroSCORE II (%) 3.24  2.84 4.22  4.83 .003
Data presented as mean  standard deviation or n (%). NYHA, New York Heart
Association; CVA, cerebrovascular accident; TIA, transient ischemic attack;
GFR, glomerular filtration rate; LV, left ventricular; RV, right ventricular; RA, right
atrial; AV, aortic valve; MV, mitral valve; CABG, coronary artery bypass grafting;
CHADS2, Congestive heart failure, Hypertension, Age> 75 years, and Diabetes
mellitus.METHODS
Study Population
From January 1990 to December 2010, 1627 patients, aged 60 years or
older, had undergone left-sided valve replacement surgery at the Asan
Medical Center (Seoul, South Korea). These patients were prospectively
registered in the database at our institution. The database includes the
baseline patient characteristics, results of cardiac evaluations, and detailed
information about surgery. Of the 1627 patients, 615 were identified as
having preoperative AF. To form a homogeneous study population, those
who had undergone concomitant right-sided valve replacement, aortic
root replacement, or correction of complex congenital heart disease were
excluded. Finally, 573 patients, aged 60 years or older (median, 65; range,
60-84), who had undergone left-sided valve replacement with either a
mechanical or bioprosthetic valve were enrolled in the present study.
The institutional ethics committee and review board at the Asan
Medical Center approved the present study (no. S2012-1476-0001). The
requirement for informed patient consent was waived owing to the
retrospective nature of the study.
Prosthesis Choice and Surgical Procedures
The attending surgeons explained the pros and cons of combining
surgical ablation with valve replacement, and the types of prosthetic
valves available (mechanical vs bioprosthetic). Decisions on the optimal
approach were made after thorough discussions, with patient input
heavily reflected. The surgical AF ablation procedures were performed
using cryoablation (n ¼ 165, 81.3%) or microwave (n ¼ 36, 17.7%),
or both sources of ablation (n ¼ 2, 1.0%). The lesion sets for the
procedure have been previously described.9 Of the present study cohort,
87 (42.9%) received left atrium ablation, and 116 (57.1%) received
biatrial ablation. During mitral valve replacement, the surgeons attempted
to retain as much subvalvular apparatus as possible using chordal-sparing
methods.
Postoperative Management
Postoperatively, all patients who underwent mechanical valve
replacement were anticoagulated with warfarin, with a target international
normalized ratio (INR) of 2.0 to 3.0. For the patients who underwent
bioprosthetic valve replacement, anticoagulation with warfarin was
routinely maintained for 3 to 6 months, with a target INR of 1.5 to 2.5.
Subsequent maintenance of anticoagulation therapy was determined
according to the individual risk factors for thromboembolism.
Postoperative AF or the absence of effective atrial contraction resulted in1908 The Journal of Thoracic and Cardiovascular Surprolonged anticoagulation therapy until both sinus rhythm and atrial
contractility had been restored. Patients with inadequate INR values
were followed up on a weekly basis until the target INR values were
achieved, after which, the warfarin doses were adjusted on an outpatient
basis every 3 months.
Patients who underwent surgical ablation were treated with a
‘‘rhythm control strategy,’’ which involved class I or III antiarrhythmicgery c June 2014
TABLE 2. Baseline characteristics stratified by prosthetic valve type
Characteristic Mechanical Bioprosthesis
P
value
Patients (n) 356 217
Age (y) 64.3  3.9 70.1  5.2 <.001
Male gender 139 (39.0) 90 (41.5) .565
NYHA functional class
I 62 (17.4) 24 (11.1)
II 139 (39.0) 74 (34.1)
III 131 (36.8) 102 (47.0)
IV 24 (6.7) 17 (7.8)
Diabetes mellitus 48 (13.5) 35 (16.1) .394
Hypertension 91 (25.6) 52 (24.0) .692
History of CVA/TIA 57 (16.0) 37 (17.1) .816
Previous cardiac surgery 27 (7.6) 20 (9.2) .531
Estimated GFR 70.0  19.6 65.9  22.0 .021
CHADS2 score
0 171 (48.0) 77 (35.5)
1 92 (25.8) 63 (29.0)
2 49 (13.8) 50 (23.0)
3 31 (8.7) 19 (8.8)
4 10 (2.8) 8 (3.7)
5 3 (0.8) 0 (0)
Echocardiographic data
LV ejection fraction (%) 54.3  9.4 52.6  11.6 .063
LV end-systolic dimension (mm) 36.8  8.2 38.0  9.8 .104
LV end-diastolic dimension (mm) 53.6  9.1 55.5  10.1 .021
Left atrial diameter (mm) 59.3  11.1 58.1  11.5 .227
RV-RA pressure gradient (mm Hg) 38.8  14.0 39.1  15.6 .841
Tricuspid regurgitation grade
0 29 (8.1) 21 (9.7)
1 102 (28.7) 58 (26.7)
2 77 (21.6) 50 (23.0)
3 72 (20.2) 43 (19.8)
4 76 (21.3) 45 (20.7)
Operation type
AV replacement 67 (18.8) 77 (35.5)
MV replacement 221 (62.1) 115 (53.0)
AV and MV replacement 68 (19.1) 25 (11.5)
Concomitant tricuspid repair 167 (46.9) 91 (41.9) .261
Other concomitant surgery
CABG 21 (5.9) 44 (20.3) <.001
Aorta replacement 6 (1.7) 8 (3.7) .165
Aortic crossclamp time (min) 90.8  41.0 98.5  43.8 .036
Cardiopulmonary bypass time (min) 168.6  41.3 151.6  64.8 .55
Logistic EuroSCORE II (%) 3.03  2.69 5.25  5.76 <.001
Data presented as mean  standard deviation or n (%). NYHA, New York Heart
Association; CVA, cerebrovascular accident; TIA, transient ischemic attack;
GFR, glomerular filtration rate; LV, left ventricular; RV, right ventricular; RA, right
atrial; AV, aortic valve; MV, mitral valve; CABG, coronary artery bypass grafting;
CHADS2, Congestive heart failure, Hypertension, Age> 75 years, and Diabetes
mellitus.
FIGURE1. Propensity scores for A, surgical ablation and B, bioprosthetic
valve. Each model had a C statistic of 0.72 and a Hosmer-Lemeshow
goodness-of-fit P ¼ .77 (A) and a C statistics of 0.43 and a
Hosmer-Lemeshow goodness-of-fit P ¼ .84 (B), indicating that both
models were adequately calibrated, with strong discrimination.
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Dmedication, when atrial arrhythmias were detected postoperatively.
Among the study cohort who received surgical ablation (n ¼ 203),
66 patients (32.5%) were discharged with class I or III medications.
Those medications were discontinued on an outpatient basis once the
restoration of normal sinus rhythm had been confirmed. The patients
who failed to achieve ‘‘AF-free’’ status after treatment with these
drugs were switched to a ‘‘rate control strategy,’’ which involvedThe Journal of Thoracic and Cardigitalis, b-blockers, or calcium channel blockers to control the
ventricular rate. The patients who did not undergo surgical ablation
were treated with a rate control strategy.
Definitions and Clinical Follow-up
The primary outcome of interest was all-cause mortality, rather than
cardiac death, because the former is the most robust and unbiased index
with no adjudication requirement.10 Other outcomes of interest included
the composite of valve-related complications. Valve-related morbidities
were recorded according to the guidelines for reporting mortality and
morbidity after cardiac valve interventions, including valve thrombosis,
embolism, bleeding, operated valve endocarditis, and reoperation.11
Clinical follow-up information was taken every 3 to 6 months on an
outpatient basis or by telephone and continued until the end of May
2012. The completeness of the data, including mortality, vital status, and
date and cause of death, was validated by the Korean National Registry
of Vital Statistics.
Statistical Analysis
Categorical variables are presented as frequencies and percentages, and
continuous variables are presented as the mean  standard deviation.
Differences in the baseline characteristics between the patient groups
according to the different surgical strategies (‘‘mechanical vs bioprosthetic
valve’’ and ‘‘ablation vs nonablation’’) were compared using Student’s
t test for continuous variables and the chi-square test or Fisher’s exact
test for categorical variables.diovascular Surgery c Volume 147, Number 6 1909
TABLE 3. Clinical outcomes
Outcome
Surgical ablation Prosthetic valve type
Ablation group
(n ¼ 203)
Control group
(n ¼ 370) P value
Mechanical
(n ¼ 356)
Bioprosthesis
(n ¼ 217) P value
All-cause mortality 30 (14.8) 136 (36.8) <.001 82 (23.0) 84 (38.7) <.001
Cardiovascular death 28 (13.8) 117 (31.6) <.001 70 (19.6) 77 (34.6) <.001
Bleeding 6 (3.0) 5 (1.4) 4 (1.1) 7 (3.2)
Thromboembolic 0 (0.0) 6 (1.6) 4 (1.1) 2 (1.0)
Arrhythmia 1 (0.5) 5 (1.4) 2 (0.6) 4 (1.8)
Heart failure 2 (1.0) 6 (1.6) 5 (1.4) 3 (1.4)
Sudden death 1 (0.5) 4 (1.1) 4 (1.1) 1 (0.5)
Unexplained 18 (8.8) 91 (24.5) 47 (13.2) 56 (25.7)
Noncardiovascular death 2 (1.0) 19 (5.2) .011 12 (3.4) 9 (4.1) .75
Respiratory disease 0 (0.0) 9 (2.4) 5 (1.4) 4 (1.7)
Sepsis 1 (0.5) 5 (1.4) 3 (0.9) 3 (1.4)
Cancer 1 (0.5) 4 (1.1) 4 (1.1) 1 (0.5)
Miscellaneous 0 (0.0) 1 (0.3) 0 (0.0) 1 (0.5)
Valve-related complications
Thromboembolic event 4 (2.0) 14 (3.8) .23 13 (3.7) 5 (2.3) .37
Anticoagulation-related hemorrhage 32 (15.8) 56 (15.1) .84 64 (18.0) 24 (11.1) .026
Prosthetic valve endocarditis 4 (2.0) 9 (2.4) .72 7 (2.0) 6 (2.8) .53
Valve reoperation 3 (1.5) 14 (3.8) .12 11 (3.1) 6 (2.8) .82
Data presented as mean  standard deviation or n (%).
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vival, and log-rank tests were used to compare the between-group
differences in survival rates. For the multivariate analyses, the Cox
proportional hazards models were used to determine the risk factors for
all-cause mortality and adverse events. The preoperative baseline
variables, surgical factors, prosthetic valve types, and the performance of
surgical ablation were evaluated in the models, and those with P . 20
on univariate analysis were candidates for the multivariate Cox models.
Multivariate analyses involved a backward elimination technique, and
only variables with P<.10 were used in the final model. The final models
were validated in 1000 bootstrap samples. For additional verification of the
results of the Cox regression analysis to compare ‘‘mechanical versus
bioprosthetic valves’’ and ‘‘ablation versus nonablation,’’ propensity score
analyses were performed.12 The propensity scores were estimated without
regard to the outcome variables by multiple logistic regression analysis.
Two propensity score models were developed that included all the
variables listed in Tables 1 and 2 (Figure 1). The propensity scores were
incorporated into the Cox regression model as covariates to calculate the
propensity-adjusted hazard ratio (HR).
All reported P values were 2-sided, and P < .05 was considered
statistically significant. SPSS software, version 19 (IBM, Armonk, NY)
was used for the statistical analysis.TABLE 4. Rhythm outcomes of ablation group at last follow-up visit
Outcomes Biatrial ablation Left-sided ablation
Patients (n) 116 87
Rhythm
Sinus rhythm 81 (69.8) 61 (70.1)
With antiarrhythmic drugs 3 (2.6) 4 (4.6)
Junctional rhythm 4 (3.4) 2 (2.3)
With antiarrhythmic drugs 1 (0.9) 0 (0.0)
PPM 12 (10.3) 2 (2.3)
Atrial fibrillation 19 (16.4) 22 (25.3)
Data presented as n (%). PPM, Permanent pacemaker.
1910 The Journal of Thoracic and Cardiovascular SurRESULTS
Baseline Characteristics
Surgical ablation was performed in 203 patients (35.4%),
and mechanical valves were implanted in 356 patients
(62.1%). The valve replacement positions were as follows:
aortic valve in 144 patients (25.1%), mitral valve in
336 patients (58.6%), and double valves in 93 patients
(16.2%). Concomitant tricuspid valve repair and coronary
artery bypass grafting (CABG) were performed in
258 (45.0%) and 65 (11.3%) patients, respectively. Of
the 258 patients who underwent tricuspid valve repair,
119 (46.1%) also underwent surgical ablation: left sided
in 39 and biatrial in 80. The baseline patient characteristics
according to the performance of surgical ablation and
the choice of prosthetic valve type are summarized in
Tables 1 and 2, respectively.
Patients who underwent concomitant surgical ablation
were biased toward female gender, larger systolic and
diastolic left ventricular (LV) dimensions, a lower history
of previous cardiac surgery, and a greater likelihood to
undergo concomitant tricuspid repair compared with those
who did not undergo surgical ablation. The estimated
surgical mortality risk validated using EuroSCORE II was
significantly greater in patients who did not undergo
surgical ablation (Table 1).
The patients who underwent bioprosthetic valve
replacement were older and were more likely to undergo
concomitantCABGthan thosewithmechanical valve replace-
ment. The EuroSCORE II score was significantly greater in
patients with bioprosthetic valve replacement (Table 2).gery c June 2014
FIGURE 2. Unadjusted Kaplan-Meier curves for all-cause mortality according to the A, performance of surgical ablation, B, valve type, C, event-free
survival according to the performance of surgical ablation, and D, event-free survival stratified by valve type. Major adverse valve-related events included
thromboembolic events, bleeding, operated valve endocarditis, and reoperation.
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DThe aortic crossclamping and cardiopulmonary bypass
times were significantly longer in patients who underwent
surgical ablation than those who did not (Table 1).
Unadjusted Clinical Outcomes and Predictors of
Mortality
Early mortality occurred in 23 patients (4.0%) and was
not significantly affected by the use of surgical ablation
(ablation vs nonablation, 3.9% vs 4.1%; P> .99) or theThe Journal of Thoracic and Carchoice of prosthetic type (mechanical vs bioprosthetic
valve, 3.1% vs 5.5%, P ¼ .19). During a median
follow-up of 58.0 months (interquartile range, 33.1 to
84.1), 166 patients (29.0%) died and 136 patients
(23.7%) experienced valve-related complications. The
details of the adverse clinical outcomes according to the
performance of surgical ablation and the choice of
prosthetic valve type are listed in Table 3. A difference in
mortality was found according to the performance ofdiovascular Surgery c Volume 147, Number 6 1911
TABLE 5. Multivariate risk factor analysis for all-cause mortality
(Cox regression)
Variable
Univariate Multivariate analysis
P value HR 95% CI P value
Age <.001 1.077 1.046-1.110 <.001
Gender .009
Diabetes mellitus .004 1.650 1.105-2.464 .014
Coronary artery disease <.001 1.618 1.097-2.387 .015
Estimated GFR .002 0.992 0.984-1.000 .052
Echocardiographic data
LV ejection fraction .017 0.982 0.968-0.996 .010
LV end-systolic dimension .004
LVend-diastolic dimension .007
Left atrial diameter .046 1.014 1.001-1.028 .038
RV-RA pressure gradient .002 1.001 1.001-1.001 .060
Other concomitant surgery
CABG <.001
Aorta replacement .009
Aortic crossclamp time .14
Cardiopulmonary bypass time <.001 1.001 1.001-1.001 <.001
Valve type .001
Surgical ablation .014 0.634 0.417-0.964 .033
Only variables with P < .20 on univariate Cox proportional hazards regression
analysis were retained. HR, Hazard ratio; CI, confidence interval; GFR, glomerular
filtration rate; LV, left ventricular; RV, right ventricular; RA, right atrial;
CABG, coronary artery bypass grafting.
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Dsurgical ablation (ablation vs nonablation, 14.8% vs
36.8%; P < .001). In the surgical ablation group,
no significant differences were found in overall survival
(log-rank test, P ¼ .44), event-free survival (log-rank test,
P ¼ .20), and freedom from cardiac death (log-rank test,
P ¼ .30) between the left-sided and biatrial groups.
The rhythm outcome at the last follow-up according to
the AF ablation lesion sets are listed in Table 4.
Figure 2 depicts the unadjusted Kaplan-Meier curves for
all-cause mortality and major event-free survival according
to the performance of surgical ablation and the choice of
prosthetic valve type. The 5- and 10-year survival rates
were 84.1% and 62.6% in the ablation group, 74.2% and
54.6% in the nonablation group (P ¼ .013, Figure 2, A),
82.2% and 68.8% in the mechanical valve group, and
71.9% and 42.8% in the bioprosthetic valve group
(P<.001; Figure 2, B), respectively. The event-free survival
tended to be superior for patients who underwent surgical
ablation than for those who did not (P ¼ .079; Figure 2,
C), and no significant difference was observed when
stratified by the choice of prosthetic valve type (P ¼ .108;
Figure 2, D).
On multivariate Cox regression analysis, several
significant and independent risk factors for all-cause
mortality emerged, including older age, diabetes mellitus,
requirement for concomitant CABG, low LV ejection
fraction, large left atrial diameter, long cardiopulmonary
bypass time, and the absence of surgical ablation. The1912 The Journal of Thoracic and Cardiovascular Surstatistical significance of a low estimated glomerular
filtration rate and pulmonary hypertension was marginal
(P ¼ .05-.10; Table 5). The prosthetic valve type, however,
did not emerge as a significant factor affecting mortality
(it was eliminated at the second stage of stepwise Cox
regression analysis).
Adjusted Clinical Outcomes: Influence of Surgical
Ablation and Prosthetic Valve Type
The propensity score adjustment models revealed that
surgical ablation was associated with a superior survival
rate (HR, 0.64; 95% confidence interval, 0.42-0.99;
P ¼ .046; Figure 3, A). In contrast, the prosthetic valve
type did not significantly affect survival after propensity
score adjustments (HR, 1.05; 95% confidence interval,
0.72-1.54, P ¼ .792; Figure 3, B). Similarly, surgical
ablation tended to decrease the overall adverse clinical
outcomes (Figure 3, C), but the prosthetic valve type did
not significantly influence event-free survival (Figure 3, D).
For additional verification, Figure 4 shows the survival
curves for 4 patient groups according to the performance
of surgical ablation and the choice of prosthetic valve
type. After adjusting for the key risk factors affecting
survival (Table 5), the curves demonstrated that the use of
surgical ablation, but not the choice of prosthetic valve
type, significantly affected the long-term survival rate
(HR, 2.085; 95% CI, 1.04-4.18; P ¼ .038; Figure 4, B).
Subgroup Analysis for Mortality
Figure 5, A and B, show the all-cause mortality for each
risk subgroup according to the multivariate risk factors
listed in Table 5. After adjusting for prespecified covariates
using the propensity score adjustment models in each
subgroup, trends were observed for a greater risk of death
associated with the absence of surgical ablation in most
subgroups (Figure 5, A). In particular, a significant
reduction in mortality by surgical ablation was
observed in patients with bioprosthetic valve implantation
(HR, 0.54; P ¼ .027), low ejection fraction (HR, 0.37;
P ¼ .041), and mitral valve implantation (HR, 0.52;
P ¼ .027). However, the choice of prosthetic valve type
did not show survival trends favoring either type of
prosthesis in any subgroup (Figure 5, B).
DISCUSSION
AF is the most common arrhythmia associated with
valvular heart disease necessitating surgical treatment.
The presence of AF has been reported to have an
adverse influence on survival13 and cardiovascular-related
complications in patients undergoing valve replacement
surgery.5,14,15 In this context, the addition of surgical
ablation in patients with valvular AF appears to have
theoretical clinical benefits. However, the benefits of
the routine performance of surgical ablation has beengery c June 2014
FIGURE 3. Survival curves adjusted by weighted Cox proportional hazards regressionmodels and propensity score for all-cause mortality according to the
A, performance of surgical ablation, B, valve type, C, event-free survival according to the performance of surgical ablation, and D, event-free survival
stratified by valve type. Major adverse valve-related events included thromboembolic events, bleeding, operated valve endocarditis, and reoperation.
HR, Hazard ratio; CI, confidence interval.
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owing to the procedural complexity and longer cardiac
ischemic time, especially for high-risk groups such as older
individuals.5,16-18
Previous studies on the outcomes of using different
prosthetic valve types in older patients found no meaningful
between-group differences in the survival rates or incidence
of complications.19-21 These cited studies, however, did notThe Journal of Thoracic and Caranalyze the clinical outcomes in a group with additional
risks of thromboembolism, such as AF, which is
important owing to its high prevalence in this population.4
The advent of surgical ablation, with its high probability
of restoring sinus rhythm, makes the decision of prosthetic
valve type more complex for older patients with valvular
AF; a bioprosthetic valve would have been routinely
recommended if AF did not coexist.1-3,22 Bioprostheticdiovascular Surgery c Volume 147, Number 6 1913
FIGURE 4. A, Unadjusted and B, adjusted survival curves for all-cause mortality of each subgroup. The subgroups were divided according to the
performance of surgical ablation and prosthetic valve type. Adjustment was conducted using Cox proportional hazards regression models.MV,Mitral valve;
TV, tricuspid valve.
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‘‘lifelong anticoagulation therapy,’’ nullifying the most
important benefit of bioprosthetic valve implantation.
Bioprosthetic valve replacement, combined with surgical
ablation, seems to be an ideal option for this particular
patient cohort. However, the efficacy of AF elimination
has been reported to be lower for older patients with giant
left atria than for younger patients,7 and the combination
of surgical ablation could increase the risks of surgery in
these vulnerable patients.
The benefit of combining mechanical valve replacement
with surgical ablation for older patients has been debated. It
has been questioned whether additional surgical ablation
might further reduce the thromboembolic risks or other
cardiovascular-related complications. Simply, mechanical
valve replacement without surgical ablation might be
sufficient; however, chronic AF has been reported to
have deleterious effects on ventricular function,13,23
which can be associated with heart failure or troublesome
rhythm-related problems long after surgery.
In the present study, we found that surgical ablation
combined with valve replacement surgery for older patients
with AF yielded superior survival rates, regardless of the
type of prosthetic valve implanted. These findings suggest
that the performance of surgical ablation is important for
improving survival but that the choice of prosthetic valve
type is not crucial.1914 The Journal of Thoracic and Cardiovascular SurRecent studies on the safety of surgical ablation have
revealed that the procedure did not increase perioperative
morbidity and risks when combined with major heart
surgery.5,16 Although combining surgical ablation with
valve replacement should be done with caution for
high-risk patient groups, we believe that the benefits of
surgical ablation on survival far outweigh the deleterious
effects of the prolonged ischemic time and increased extent
of surgery.
Our study has showed that the survival benefits of
surgical ablation were more prominent in the subgroup
with LV dysfunction (Figure 5, A). LV dysfunction is known
to be associated with increased surgical mortality and
morbidity in patients undergoing cardiac surgery.14 Thus,
performing surgical ablation in this group has been
controversial. However, it has been demonstrated that
restoring atrial contraction and atrioventricular synchrony
by the addition of surgical ablation can increase cardiac
output and delay the progression of heart failure.15,23 This
could account for the marked survival benefit to patients
with LV dysfunction in our subgroup analysis. This
finding indicates that surgical ablation can be performed
with an acceptable safety profile in this high-risk group.
Lifelong anticoagulation therapy after valve replacement
surgery is an important determining factor in the choice of
prosthetic valve type, when surgical ablation is involved.
For the group with bioprosthetic valve implantation, thegery c June 2014
FIGURE 5. A, Adjusted hazard ratios (HRs) for all-cause mortality according to A, the performance of surgical ablation in subgroups according to
multivariate risk factors, and B, the choice of prosthetic valve type in subgroups according to multivariate risk factors. HRs were adjusted by weighted
Cox proportional hazards regression models and propensity scores. CI, Confidence interval; AF, atrial fibrillation.
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eliminated after restoration of sinus rhythm by surgical
ablation. Discontinuation of anticoagulation can be of great
benefit to older patients by reducing the risks of major
bleeding.24 Our subgroup analysis showed significant
survival benefits with the addition of surgical ablation to
the bioprosthetic valve group (Figure 5, A). This resultThe Journal of Thoracic and Carcould be attributed to (1) a lowered risk of thromboembo-
lism inherent to AF owing to the restoration of sinus
rhythm; (2) a reduced rate of anticoagulation-related
hemorrhagic complications; and (3) improved hemo-
dynamic performance with surgical ablation.23 Along
with the ‘‘no-need-for-anticoagulation,’’ the significant
survival benefits of surgical ablation in the bioprostheticdiovascular Surgery c Volume 147, Number 6 1915
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prosthetic valve type for older patients with valvular AF.
In contrast to the bioprosthetic valve group, the theore-
tical benefits of surgical ablation in the mechanical valve
group could have been limited by the inevitable lifelong
anticoagulation therapy required. However, the beneficial
effects of improved LV and tricuspid valve function and a
reduced risk of thromboembolic events after surgical
AF ablation in patients undergoing mechanical valve
replacement have been previously reported.8,17,18,23 In
support of these results, the present study has shown that
concomitant AF ablation revealed a trend toward
favorable survival in patients undergoing mechanical
valve replacement (HR, 0.76) although it did not reach
statistical significance (P ¼ .44). Pending the results from
studies of a larger population, we believe that AF ablation
should be always considered, even in older patients
undergoing mechanical valve replacement, to improve the
overall clinical and hemodynamic outcomes and to realize
the consequent potential survival benefits.
Previous studies on the clinical effect of choosing
different prosthetic valve types have shown mixed
results regarding survival and postoperative complica-
tions.1-3,22,25 In our study, the difference in survival rates
according to prosthetic valve types (Figure 2, B) was mainly
attributed to age, but it disappeared after appropriate
statistical adjustments (Figure 3, B). In addition, our
subgroup analysis showed that the survival benefits did
not favor any particular prosthetic valve type (Figure 5,
B). Both results indicate that survival does not vary
according to the prosthetic valve type. Therefore, the choice
of prosthetic valve type should be made, considering the
overall conditions of the patient and the feasibility of
surgical ablation for older patients with valvular AF.
Study Limitations
This was a retrospective and nonrandomized study of
observational data. Hence, the results could have been
influenced by unmeasured confounders, despite rigorous
statistical adjustments. In addition, the present study incor-
porated 20 years of data, implicating the lack of uniformity
of surgical ablation in terms of ablated atrial lesions and
ablation energy sources. In addition, the study population
included a mixed bag of cases, including single- and
double-valve replacements, with and without CABG and
aortic and mitral positions. This heterogeneity of the study
population could have affected the study results.
CONCLUSIONS
Long-term survival after valve replacement surgery in
older patients with AF will be affected by several
preoperative characteristics, such as diabetes, coronary
artery disease, heart failure, and the addition of surgical
ablation, but not by the choice of prosthetic valve type.1916 The Journal of Thoracic and Cardiovascular SurOur findings suggest that surgical AF ablation should
always be considered as a concomitant procedure for older
patients with valvular AF, with a liberal choice of prosthetic
valve type according to the conditions and expectations of
the patient, not the perceived superiority of 1 valve type
to another.References
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